MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · Real-Time Price · USD
1.480
+0.120 (8.82%)
Dec 24, 2025, 1:00 PM EST - Market closed
MAIA Biotechnology Employees
MAIA Biotechnology had 13 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,718,411
Market Cap
54.81M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 13 | 0 | - |
| Dec 31, 2023 | 13 | -5 | -27.78% |
| Dec 31, 2022 | 18 | 9 | 100.00% |
| Dec 31, 2021 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MAIA News
- 14 hours ago - MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings - GlobeNewsWire
- 8 days ago - MAIA Biotechnology Announces $1.51 Million Private Placement - GlobeNewsWire
- 13 days ago - MAIA's Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates - GlobeNewsWire
- 14 days ago - MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach - GlobeNewsWire
- 23 days ago - MAIA Biotechnology Announces Open Market Purchases by CEO and Directors - GlobeNewsWire
- 4 weeks ago - MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025 - GlobeNewsWire
- 6 weeks ago - Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - GlobeNewsWire
- 2 months ago - MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire